Metabolic syndrome is associated with increased breast cancer risk: A systematic review with meta-analysis

International Journal of Breast Cancer

Volumn 2014, Issue , 2014, Pages

  Bhandari, Ruchi ^a   Kelley, George A ^a   Hartley, Tara A ^b   Rockett, Ian R H ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER RISK; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; METABOLIC SYNDROME X; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TUMOR INVASION;

EID: 85013885176     PISSN: 20903170     EISSN: 20903189     Source Type: Journal    
DOI: 10.1155/2014/189384     Document Type: Review

References (118)

1. J. Ferlay, I. Soerjomataram, M. Ervik et al. , GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, International Agency for Research on Cancer, Lyon, France, 2013.
2. National Cancer Institute. Breast Cancer-Risk Factors, http://www.cancer.gov/cancertopics/wyntk/breast/page4.
3. S. M. Grundy, H. B. Brewer Jr. , J. I. Cleeman, S. C. Smith Jr. , and C. Lenfant, "Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition," Circulation, vol. 109, no. 3, pp. 433-438, 2004.
4. G. M. Reaven, "Role of insulin resistance in human disease," Diabetes, vol. 37, no. 12, pp. 1595-1607, 1988.
5. World Health Organization, Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation, World Health Organization, Geneva, Switzerland, 1999.
6. "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment ofHigh BloodCholesterol inAdults (Adult Treatment Panel III) final report," Circulation, vol. 106, no. 25, pp. 3143-3421, 2002.
7. S. M. Grundy, J. I. Cleeman, S. R. Daniels et al. , "Diagnosis and management of the metabolic syndrome: an American Heart Association/NationalHeart, Lung, and Blood Institute scientific statement," Circulation, vol. 112, no. 17, pp. 2735-2752, 2005.
8. K. G. Alberti, P. Zimmet, and J. Shaw, "The metabolic syndrome-a new worldwide definition," The Lancet, vol. 366, no. 9491, pp. 1059-1062, 2005.
9. S. M. Grundy, "Metabolic syndrome pandemic," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, pp. 629-636, 2008.
10. K. Esposito, P. Chiodini, A. Capuano et al. , "Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis," Menopause, vol. 20, no. 12, pp. 1301-1309, 2013.
11. K. Esposito, P. Chiodini, A. Capuano et al. , "Effect ofmetabolic syndrome and its components on prostate cancer risk: metaanalysis," Journal of Endocrinological Investigation, vol. 36, no. 2, pp. 132-139, 2013.
12. K. Esposito, P. Chiodini, A. Capuano et al. , "Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis," Endocrine, vol. 44, no. 3, pp. 634-647, 2013.
13. Y. Osaki, S.-I. Taniguchi, A. Tahara, M. Okamoto, and T. Kishimoto, "Metabolic syndrome and incidence of liver and breast cancers in Japan," Cancer Epidemiology, vol. 36, no. 2, pp. 141-147, 2012.
14. V. Rosato, C. Bosetti, R. Talamini et al. , "Metabolic syndrome and the risk of breast cancer in postmenopausal women," Annals of Oncology, vol. 22, no. 12, pp. 2687-2692, 2011.
15. V. Rosato, A. Tavani, C. Bosetti et al. , "Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and metaanalysis," Metabolism: Clinical and Experimental, vol. 60, no. 10, pp. 1372-1378, 2011.
16. P. A. van den Brandt, D. Spiegelman, S.-S. Yaun et al. , "Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk," American Journal of Epidemiology, vol. 152, no. 6, pp. 514-527, 2000.
17. Z. Huang, S. E. Hankinson, G. A. Colditz et al. , "Dual effects of weight and weight gain on breast cancer risk," Journal of the American Medical Association, vol. 278, no. 17, pp. 1407-1411, 1997.
18. M. Harvie, L. Hooper, and A. H. Howell, "Central obesity and breast cancer risk: a systematic review," Obesity Reviews, vol. 4, no. 3, pp. 157-173, 2003.
19. K. B. Michels, C. G. Solomon, F. B. Hu et al. , "Type 2 diabetes and subsequent incidence of breast cancer in the nurses health study," Diabetes Care, vol. 26, no. 6, pp. 1752-1758, 2003.
20. F. de Waard and E. A. Baanders van Halewijn, "A prospective study in general practice on breast cancer risk in postmenopausal women," International Journal of Cancer, vol. 14, no. 2, pp. 153-160, 1974.
21. P. J. Mink, E. Shahar, W. D. Rosamond, A. J. Alberg, and A. R. Folsom, "Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study," The American Journal of Epidemiology, vol. 156, no. 4, pp. 349-352, 2002.
22. S. A. Tornberg, L.-E. Holm, and J. M. Carstensen, "Breast cancer risk in relation to serum cholesterol, serum beta-lipoprotein, height, weight, and blood pressure," Acta Oncologica, vol. 27, no. 1, pp. 31-37, 1988.
23. M. Soler, L. Chatenoud, E. Negri, F. Parazzini, S. Franceschi, and C. La Vecchia, "Hypertension and hormone-related neoplasms in women," Hypertension, vol. 34, no. 2, pp. 320-325, 1999.
24. J. A. Largent, A. J. McEligot, A. Ziogas et al. , "Hypertension, diuretics and breast cancer risk," Journal of Human Hypertension, vol. 20, no. 10, pp. 727-732, 2006.
25. G. Llaverias, C. Danilo, I. Mercier et al. , "Role of cholesterol in the development and progression of breast cancer," The American Journal of Pathology, vol. 178, no. 1, pp. 402-412, 2011.
26. M. Gerber, F. Cavallo, E. Marubini et al. , "Liposoluble vitamins and lipid parameters in breast cancer. A joint study in northern Italy and southern France," International Journal of Cancer, vol. 42, no. 4, pp. 489-494, 1988.
27. C. G. Alexopoulos, B. Blatsios, and A. Avgerinos, "Serum lipids and lipoprotein disorders in cancer patients," Cancer, vol. 60, no. 12, pp. 3065-3070, 1987.
28. S. C. Larsson, C. S. Mantzoros, and A. Wolk, "Diabetes mellitus and risk of breast cancer: a meta-analysis," International Journal of Cancer, vol. 121, no. 4, pp. 856-862, 2007.
29. M. T. Goodman, J. B. Cologne, H. Moriwaki, M. Vaeth, and K. Mabuchi, "Risk factors for primary breast cancer in Japan: 8- year follow-up of atomic bomb survivors," Preventive Medicine, vol. 26, no. 1, pp. 144-153, 1997.
30. E. Weiderpass, G. Gridley, I. Persson, O. Nyren, A. Ekbom, and H. O. Adami, "Risk of endometrial and breast cancer in patients with diabetes mellitus," International Journal of Cancer, vol. 71, pp. 360-363, 1997.
31. L. Wideroff, G. Gridley, L. Mellemkjaer et al. , "Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in denmark," Journal of the National Cancer Institute, vol. 89, no. 18, pp. 1360-1365, 1997.
32. S. H. Jee, H. J. Sun, H. Ohrr et al. , "Fasting serum glucose level and cancer risk in Korean men and women," The Journal of the AmericanMedical Association, vol. 293, no. 2, pp. 194-202, 2005.
33. P. Boyle, M. Boniol, and A. Koechlin, "Diabetes and breast cancer risk: a meta-analysis," British Journal of Cancer, vol. 107, pp. 1608-1617, 2012.
34. L. M. Morimoto, E. White, Z. Chen et al. , "Obesity, body size, and risk of postmenopausal breast cancer: the womens health initiative (United States)," Cancer Causes and Control, vol. 13, no. 8, pp. 741-751, 2002.
35. World Cancer Research Fund, Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective, American Institute for Cancer Research, Washington, DC, USA, 2nd edition, 2007.
36. G. Ursin, M. P. Longnecker, R. W. Haile, and S. Greenland, "A meta-analysis of body mass index and risk of premenopausal breast cancer," Epidemiology, vol. 6, no. 2, pp. 137-141, 1995.
37. D. R. Pathak and A. S. Whittemore, "Combined effects of body size, parity, and menstrual events on breast cancer incidence in seven countries,"TheAmerican Journal of Epidemiology, vol. 135, no. 2, pp. 153-168, 1992.
38. S. L. Peacock, E. White, J. R. Daling, L. F. Voigt, and K. E. Malone, "Relation between obesity and breast cancer in young women," American Journal of Epidemiology, vol. 149, no. 4, pp. 339-346, 1999.
39. J. Manjer, R. Kaaks, E. Riboli, and G. Berglund, "Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucosemetabolism: a prospective studywithin the Malmö Preventive Project," European Journal of Cancer Prevention, vol. 10, no. 1, pp. 33-42, 2001.
40. P. H. M. Peeters, P. A. H. van Noord, A. W. Hoes, J. Fracheboud, C. H. F. Gimbrère, and D. E. Grobbee, "Hypertension and breast cancer risk in a 19-year follow-up study (the DOM cohort)," Journal of Hypertension, vol. 18, no. 3, pp. 249-254, 2000.
41. T. Agurs-Collins, K. S. Kim, G. M. Dunston, and L. L. Adams- Campbell, "Plasma lipid alterations in African-American women with breast cancer," Journal of Cancer Research and Clinical Oncology, vol. 124, no. 3-4, pp. 186-190, 1998.
42. M. Ha, J. Sung, and Y.-M. Song, "Serum total cholesterol and the risk of breast cancer in postmenopausal Korean women," Cancer Causes and Control, vol. 20, no. 7, pp. 1055-1060, 2009.
43. C. Agnoli, F. Berrino, C. A. Abagnato et al. , "Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study," Nutrition, Metabolism and Cardiovascular Diseases, vol. 20, no. 1, pp. 41-48, 2010.
44. L. M. Beaulieu, B. R. Whitley, T. F. Wiesner et al. , "Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle," BioEssays, vol. 29, no. 10, pp. 1029- 1038, 2007.
45. T. Bjørge, A. Lukanova, H. Jonsson et al. , "Metabolic syndrome and breast cancer in theMe-Can (metabolic syndrome and cancer) project," Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 7, pp. 1737-1745, 2010.
46. I. Capasso, E. Esposito, F. Pentimalli et al. , "Metabolic syndrome affects breast-cancer risk in postmenopausal women: National Cancer Institute of Naples experience," Cancer Biology and Therapy, vol. 10, no. 12, pp. 1240-1243, 2010.
47. L. A. Healy, A. M. Ryan, P. Carroll et al. , "Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer," Clinical Oncology, vol. 22, no. 4, pp. 281-288, 2010.
48. G. C. Kabat, M. Kim, R. T. Chlebowski et al. , "A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer," Cancer Epidemiology, Biomarkers & Prevention, vol. 18, no. 7, pp. 2046-2053, 2009.
49. B. Maiti, M. N. Kundranda, T. P. Spiro, and H. A. Daw, "The association of metabolic syndrome with triple-negative breast cancer," Breast Cancer Research and Treatment, vol. 121, no. 2, pp. 479-483, 2010.
50. L. A. M. Porto, K. J. B. Lora, J. C. M. Soares, and L. O. B. F. Costa, "Metabolic syndrome is an independent risk factor for breast cancer," Archives of Gynecology and Obstetrics, vol. 284, no. 5, pp. 1271-1276, 2011.
51. A. L. Ronco, E. De Stéfani, H. Deneo-Pellegrini, and A. Quarneti, "Diabetes, overweight and risk of postmenopausal breast cancer: a case-control study in Uruguay," Asian Pacific Journal of Cancer Prevention, vol. 13, no. 1, pp. 139-146, 2012.
52. D. P. Rose, S. M. Haffner, and J. Baillargeon, "Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women," Endocrine Reviews, vol. 28, no. 7, pp. 763-777, 2007.
53. D. Sinagra, C. Amato, A. M. Scarpilta et al. , "Metabolic syndrome and breast cancer risk," European Review forMedical and Pharmacological Sciences, vol. 6, pp. 55-59, 2002.
54. L. Vona-Davis, M. Howard-Mcnatt, and D. P. Rose, "Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer," Obesity Reviews, vol. 8, no. 5, pp. 395-408, 2007.
55. F. Xue and K. B. Michels, "Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence," The American Journal of Clinical Nutrition, vol. 86, no. 3, pp. s823-s835, 2007.
56. K. Esposito, P. Chiodini, A. Colao, A. Lenzi, and D. Giugliano, "Metabolic syndrome and risk of cancer: a systematic review and meta-analysis," Diabetes Care, vol. 35, no. 11, pp. 2402-2411, 2012.
57. D. P. Rose, D. Komninou, and G. D. Stephenson, "Obesity, adipocytokines, and insulin resistance in breast cancer," Obesity Reviews, vol. 5, no. 3, pp. 153-165, 2004.
58. S. Liao, J. Li, W. Wei et al. , "Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature," Asian Pacific Journal of Cancer Prevention, vol. 12, no. 4, pp. 1061-1065, 2011.
59. E. Giovannucci, D. M. Harlan, M. C. Archer et al. , "Diabetes and cancer: a consensus report," Diabetes Care, vol. 33, no. 7, pp. 1674-1685, 2010.
60. T. Jarde, S. Perrier, M. P. Vasson, and F. Caldefie-Chezet, "Molecular mechanisms of leptin and adiponectin in breast cancer," European Journal of Cancer, vol. 47, no. 1, pp. 33-43, 2011.
61. J. E. Goldberg and K. L. Schwertfeger, "Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics," Current Drug Targets, vol. 11, no. 9, pp. 1133-1146, 2010.
62. J. L. F. Bosco, "Selected medications, cardiometabolic risk factors, and breast cancer risk," Proquest Dissertations and Theses UMI 3445685, 2011.
63. M. Inoue, M. Noda, N. Kurahashi et al. , "Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan," European Journal of Cancer Prevention, vol. 18, no. 3, pp. 240-247, 2009.
64. A. Russo, M. Autelitano, and L. Bisanti, "Metabolic syndrome and cancer risk," European Journal of Cancer, vol. 44, no. 2, pp. 293-297, 2008.
65. G. Glass, B. McGaw, and M. L. Smith, Meta-Analysis in Social Research, Sage, 1981.
66. J. Cohen, "Weighted kappa: nominal scale agreement provision for scaled disagreement or partial credit," Psychological Bulletin, vol. 70, no. 4, pp. 213-220, 1968.
67. J. P. Vandenbroucke, E. Von Elm, D. G. Altman et al. , "Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration," Gaceta Sanitaria, vol. 23, no. 2, pp. 158. e1-158. e28, 2009.
68. R. DerSimonian and N. Laird, "Meta-analysis in clinical trials," Controlled Clinical Trials, vol. 7, no. 3, pp. 177-188, 1986.
69. W. G. Cochran, "Research techniques in the study of human beings," The Milbank Memorial Fund Quarterly, vol. 33, no. 2, pp. 121-136, 1955.
70. J. P. T. Higgins and S. G. Thompson, "Quantifying heterogeneity in ameta-analysis," Statistics inMedicine, vol. 21, no. 11, pp. 1539- 1558, 2002.
71. S. Duval and R. Tweedie, "Trim and fill: a simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis," Biometrics, vol. 56, no. 2, pp. 455-463, 2000.
72. R. Rosenthal, "The file drawer problem and tolerance for null results," Psychological Bulletin, vol. 86, no. 3, pp. 638-641, 1979.
73. M. Borenstein, L. Hedges, J. Higgins, and H. Rothstein, Comprehensive Meta Analysis Version 2, Biostat, Englewood, NJ, USA, 2005.
74. J. Brunet, A. Vazquez-Martin, R. Colomer, B. Graña-Suarez, B. Martin-Castillo, and J. A. Menendez, "BRCA1 and acetyl- CoA carboxylase: the metabolic syndrome of breast cancer," Molecular Carcinogenesis, vol. 47, no. 2, pp. 157-163, 2008.
75. E. Bugianesi, "Review article: steatosis, the metabolic syndrome and cancer," Alimentary Pharmacology & Therapeutics, vol. 22, supplement 2, pp. 40-43, 2005.
76. S. M. Conroy, L. M. Butler, D. Harvey et al. , "Metabolic syndrome and mammographic density: the Study of Womens Health Across the Nation," International Journal of Cancer, vol. 129, no. 7, pp. 1699-1707, 2011.
77. A.-S. Furberg, M. B. Veierød, T. Wilsgaard, L. Berstein, and I. Thune, "Serum high density lipoprotein cholesterol, metabolic profile, and breast cancer risk," Journal of the National Cancer Institute, vol. 96, no. 15, pp. 1152-1160, 2004.
78. A.-S. Furberg, G. Jasienska, N. Bjurstam et al. , "Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA study," Cancer Epidemiology, Biomarkers and Prevention, vol. 14, no. 1, pp. 33-40, 2005.
79. H. Kuhl, "Breast cancer risk in the WHI study: the problem of obesity," Maturitas, vol. 51, no. 1, pp. 83-97, 2005.
80. S. W. Oh, C. Y. Park, E. S. Lee et al. , "Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study," Breast Cancer Research, vol. 13, no. 2, article R34, 2011.
81. M. N. Okobia, C. H. Bunker, J. M. Zmuda et al. , "Anthropometry and breast cancer risk in Nigerian women," Breast Journal, vol. 12, no. 5, pp. 462-466, 2006.
82. P. J. Wysocki and B. Wierusz-Wysocka, "Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin," Expert Review ofMolecular Diagnostics, vol. 10, no. 4, pp. 509-519, 2010.
83. C. Y. Yang, C. Y. Peng, Y. C. Liu, W. Z. Chen, and W. K. Chiou, "Surface anthropometric indices in obesity-related metabolic diseases and cancers," Chang Gung Medical Journal, vol. 34, no. 1, pp. 1-22, 2011.
84. A. G. Antoniadis, E. T. Petridou, C. N. Antonopoulos et al. , "Insulin resistance in relation to melanoma risk," Melanoma Research, vol. 21, no. 6, pp. 541-546, 2011.
85. J. Arends, "Metabolism in cancer patients," Anticancer Research, vol. 30, no. 5, pp. 1863-1868, 2010.
86. P. A. Carroll, L. Healy, J. Lysaght et al. , "Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer," Molecular Carcinogenesis, vol. 50, no. 8, pp. 643-651, 2011.
87. S. L. Doyle, C. L. Donohoe, J. Lysaght, and J. V. Reynolds, "Visceral obesity, metabolic syndrome, insulin resistance and cancer," Proceedings of the Nutrition Society, vol. 71, no. 1, pp. 181-189, 2012.
88. M. M. Gaudet, R. T. Falk, G. L. Gierach et al. , "Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women?" Cancer Epidemiology, vol. 34, no. 5, pp. 580-586, 2010.
89. H. R. Harris, W. C. Willett, K. L. Terry, and K. B. Michels, "Body fat distribution and risk of premenopausal breast cancer in the nurses health study II," Journal of the National Cancer Institute, vol. 103, no. 3, pp. 273-278, 2011.
90. C. Heidemann, H. Boeing, T. Pischon, U. Nöthlings, H.-G. Joost, and M. B. Schulze, "Association of a diabetes risk score with risk of myocardial infarction, stroke, specific types of cancer, and mortality: a prospective study in the European Prospective Investigation into Cancer and Nutrition (EPIC)- Potsdamcohort," European Journal of Epidemiology, vol. 24, no. 6, pp. 281-288, 2009.
91. L.-N. Liu, C. Miaskowski, J.-S. Wang, S.-C. Chen, and M.-L. Chen, "Accuracy of body mass index to determine obesity in women with breast cancer: an observational study of Taiwanese sample," International Journal of Nursing Studies, vol. 47, no. 8, pp. 994-1000, 2010.
92. K. K. Ness, J. M. Oakes, J. A. Punyko, K. S. Baker, and J. G. Gurney, "Prevalence of the metabolic syndrome in relation to self-reported cancer history,"Annals of Epidemiology, vol. 15, no. 3, pp. 202-206, 2005.
93. S. Papaioannou and J. Tzafettas, "Anovulation with or without PCO, hyperandrogenaemia and hyperinsulinaemia as promoters of endometrial and breast cancer," Best Practice and Research: Clinical Obstetrics and Gynaecology, vol. 24, no. 1, pp. 19-27, 2010.
94. P. Pasanisi, F. Berrino, M. De Petris, E. Venturelli, A. Mastroianni, and S. Panico, "Metabolic syndrome as a prognostic factor for breast cancer recurrences," International Journal of Cancer, vol. 119, no. 1, pp. 236-238, 2006.
95. S. Rinaldi, T. J. Key, P. H. M. Peeters et al. , "Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort," International Journal of Cancer, vol. 118, no. 11, pp. 2832-2839, 2006.
96. B. A. Stoll, "Timing of weight gain in relation to breast cancer risk," Annals of Oncology, vol. 6, no. 3, pp. 245-248, 1995.
97. M. Pollak, "Insulin, insulin-like growth factors and neoplasia," Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 22, no. 4, pp. 625-638, 2008.
98. E. T. Chesney, S. C. Davis, L. Duggan, and S. Natarajan, "Does metabolic syndrome increase risk for certain cancers?" American Journal forNurse Practitioners, vol. 14, pp. 25-32, 2010.
99. R. L. Ahmed-Saucedo, "Preview Epidemiological associations of metabolic factors with cancer risk and cancer late effects," Proquest Dissertations & Theses UMI 3200570, 2006.
100. S. M. Conroy, Physical activity, metabolic syndrome and insulin resistance in relation to mammographic density [ProQuest Dissertations &Thesis], 2009, UMI 3379558.
101. G. Ibarra-Mejia, "Exogenous environmental factors and susceptibility for breast cancer in Mexican American women," ProQuest Dissertations and Theses UMI 3196421, 2005.
102. C. Pichard, G. Plu-Bureau, M. Neves-e Castro, and A. Gompel, "Insulin resistance, obesity and breast cancer risk," Maturitas, vol. 60, no. 1, pp. 19-30, 2008.
103. G. D. Stephenson and D. P. Rose, "Breast cancer and obesity: an update," Nutrition and Cancer, vol. 45, no. 1, pp. 1-16, 2003.
104. D. Goodman-Gruen and E. Barrett-Connor, "Sex hormonebinding globulin and glucose tolerance in postmenopausal women: the Rancho Bernardo study," Diabetes Care, vol. 20, no. 4, pp. 645-649, 1997.
105. K. Sherif, H. Kushner, and B. E. Falkner, "Sex hormone-binding globulin and insulin resistance in African-American women," Metabolism, vol. 47, no. 1, pp. 70-74, 1998.
106. A. S. Cikim, N. Ozbey, E. Sencer, S. Molvalilar, and Y. Orhan, "Associations among sex hormone binding globulin concentrations and characteristics of the metabolic syndrome in obese women," Diabetes, Nutrition and Metabolism-Clinical and Experimental, vol. 17, no. 5, pp. 290-295, 2004.
107. S. Hajamor, J.-P. Després, C. Couillard et al. , "Relationship between sex hormone-binding globulin levels and features of the metabolic syndrome," Metabolism-Clinical and Experimental, vol. 52, no. 6, pp. 724-730, 2003.
108. L. Vona-Davis and D. P. Rose, "Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression," Endocrine-Related Cancer, vol. 14, no. 2, pp. 189- 206, 2007.
109. S. Klein, S. W. Coppack, V. Mohamed-Ali, and M. Landt, "Adipose tissue leptin production and plasma leptin kinetics in humans," Diabetes, vol. 45, no. 3, pp. 984-987, 1996.
110. S. Fischer, M. Hanefeld, S. M. Haffner et al. , "Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass," Acta Diabetologica, vol. 39, no. 3, pp. 105-110, 2002.
111. M. Wauters, R. V. Considine, J. S. Yudkin, F. Peiffer, I. de Leeuw, and L. F. van Gaal, "Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion," Hormone and Metabolic Research, vol. 35, no. 2, pp. 92-96, 2003.
112. P. W. Franks, S. Brage, J. Luanet al. , "Leptinpredictsaworsening of the features of the metabolic syndrome independently of obesity," Obesity Research, vol. 13, no. 8, pp. 1476-1484, 2005.
113. M. C. Chu, P. Cosper, F. Orio, E. Carmina, and R. A. Lobo, "Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin," The American Journal of Obstetrics and Gynecology, vol. 194, no. 1, pp. 100-104, 2006.
114. P. Somasundar, D. W. McFadden, S. M. Hileman, and L. Vona- Davis, "Leptin is a growth factor in cancer," Journal of Surgical Research, vol. 116, no. 2, pp. 337-349, 2004.
115. M. P. Scheid and G. Sweeney, "The role of adiponectin signaling in metabolic syndrome and cancer," Reviews in Endocrine and Metabolic Disorders, vol. 15, no. 2, pp. 157-167, 2014.
116. M. L. Panno, M. Salerno, V. Pezzi et al. , "Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF-7 cells," Journal of Cancer Research and Clinical Oncology, vol. 122, no. 12, pp. 745- 749, 1996.
117. S. R. Plymate, L. A. Matej, R. E. Jones, and K. E. Friedl, "Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin," The Journal of Clinical Endocrinology & Metabolism, vol. 67, no. 3, pp. 460-464, 1988.
118. G. Gregoire, F. Derderian, and J. Le Lorier, "Selecting the language of the publications included in a meta-analysis: is there a Tower ofBabel bias?" Journal of Clinical Epidemiology, vol. 48, no. 1, pp. 159-163, 1995.